Skip to content

Patient Reported Outcomes in the Medical Oncology Setting (iPROMOS)

Implementing Patient Reported Outcomes (PROs) in the Medical Oncology Setting: A stepped wedge study to implement PROs into the clinical practice of the medical oncology outpatients department

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618000398202
Acronym
iPROMOS
Enrollment
461
Registered
2018-03-20
Start date
2018-03-21
Completion date
2018-06-19
Last updated
2023-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Strong evidence published in 2016 showed that routine collection of Patient Reported Outcomes (PROs) significantly improves the survival and quality of life of medical oncology patients in the US and Europe (Basch, 2016). Despite these findings, PROs are not routinely used in Australian oncology care. The purpose of this translational research project is to understand how PROs can be implemented in a medical oncology setting to improve personalized care.The purpose of this project is to explore the feasibility, acceptance and effectiveness of implementing Patient Reported Outcomes (PRO) measurement in routine medical oncology outpatient care. Who is it for? You may be eligible for this study if you are over the age of 18 and are a patient attending for medical review in a medical oncology clinic enrolled in the study. Study details All patients attending the enrolled clinics will be approached to report their symptoms on a touchscreen, which will generate a report. A copy of the report will be given to participants, and a copy put in the patients medical record. This information will be available to all clinicians in the multidisciplinary team. The study will be facilitated and evaluated using an implementation science approach throughout. It is hope that results from this study will provide evidence and guide future research into the implementation of this complex intervention into the clinical setting. There are significant benefits in the clinical trials to date, and it is hoped that this project can better inform the translation of this into clinical practice.

Interventions

When patients attend the allocated clinic they will be approached to report their symptoms via a touchscreen computer. The PROM chosen is the CTCAE-PRO that Basch et al (2016) used in their clinical trial. A report will be printed, and a copy will be given to the patient and a copy put into their medical record. The intervention will be monitored by completion rates and response rates of clinicians. Basch et al (2016). JCO 30(34), 4249-4255. The study will be facilitated by an oncology nurse w

When patients attend the allocated clinic they will be approached to report their symptoms via a touchscreen computer. The PROM chosen is the CTCAE-PRO that Basch et al (2016) used in their clinical trial. A report will be printed, and a copy will be given to the patient and a copy put into their medical record. The intervention will be monitored by completion rates and response rates of clinicians. Basch et al (2016). JCO 30(34), 4249-4255. The study will be facilitated by an oncology nurse with more than 5 years experience.

Sponsors

Natasha Roberts
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Other
Primary purpose
Prevention
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. patients attending for medical review in randomized medical oncology outpatient clinics 2. Staff caring for the patients attending the randomized medical oncology outpatient clinics

Exclusion criteria

1. Difficulty completing or understanding the PRO forms including significant cognitive impairment, visual difficulties or non-English speaking background 2. Staff that are not willing to participate

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 22, 2026